A novel strategy to mitigate the hyperinflammatory response to COVID-19 by targeting leukotrienes

CD Funk, A Ardakani - Frontiers in pharmacology, 2020 - frontiersin.org
SARS-CoV-2 causing coronavirus disease 2019 (COVID-19) has wreaked havoc during the
global pandemic of 2020 infecting millions and leaving over a half million dead. As a new …

The leukotriene receptor antagonist montelukast as a potential COVID-19 therapeutic

L Aigner, F Pietrantonio… - Frontiers in molecular …, 2020 - frontiersin.org
The emergence and global impact of COVID-19 has focused the scientific and medical
community on the pivotal influential role of respiratory viruses as causes of severe …

Targeting inflammation and cytokine storm in COVID-19

Q Huang, X Wu, X Zheng, S Luo, S Xu… - Pharmacological Research, 2020 - Elsevier
The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 9.2 million …

Montelukast inhibits platelet activation induced by plasma from COVID-19 patients

M Camera, P Canzano, M Brambilla… - Frontiers in …, 2022 - frontiersin.org
Leukotrienes are important pro-inflammatory lipid mediators derived from the arachidonic
acid metabolism. In particular, cysteinyl leukotrienes, namely LTC4, LTD4, and LTE4 are …

Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity

HM Al-Kuraishy, AI Al-Gareeb, YQ Almulaiky… - European journal of …, 2021 - Elsevier
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), the responsible agent for
the coronavirus disease 2019 (Covid-19), has its entry point through interaction with …

[PDF][PDF] Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy

P Conti, A Caraffa, CE Gallenga, R Ross… - J Biol Regul Homeost …, 2020 - researchgate.net
SARS-Cov-2 infection causes local and systemic inflammation mediated by pro-
inflammatory cytokines and COX-2 eicosanoid products with metabolic dysfunction and …

[HTML][HTML] Dexamethasone, pro‐resolving lipid mediators and resolution of inflammation in COVID‐19

E Andreakos, M Papadaki, CN Serhan - Allergy, 2021 - ncbi.nlm.nih.gov
Coronavirus disease-19 (COVID-19) is a new disease caused by SARS-CoV-2. Since the
beginning of 2020, it has become one of the main challenges of our times, causing a high …

Review on therapeutic targets for COVID-19: insights from cytokine storm

ML de Mélo Silva Júnior, LMA de Souza… - Postgraduate …, 2021 - academic.oup.com
Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been
caused the greatest pandemic of our century. Many of the deaths related to it are due to a …

[HTML][HTML] High levels of eicosanoids and docosanoids in the lungs of intubated COVID‐19 patients

AS Archambault, Y Zaid, V Rakotoarivelo… - The FASEB …, 2021 - ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus 2 is responsible for coronavirus disease
2019 (COVID‐19). While COVID‐19 is often benign, a subset of patients develops severe …

SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions

P Asrani, MI Hassan - Molecular and Cellular Biochemistry, 2021 - Springer
The recent exposure of novel coronavirus strain, severe acute respiratory syndrome (SARS-
CoV-2) has spread to different countries at an alarming rate. Faster transmission rate and …